Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29718585 | 1.00 | POLQ (0.61) | POLQPTGS2AKR1B1TDP1IDO1 | |
| Hydrochloric Acid SCHEMBL2529825 | 0.98 | POLQ (0.59) | POLQPTGS2AKR1B1TDP1IDO1 | |
| Methyl Alcohol SCHEMBL8011354 | 0.96 | POLQ (0.62) | POLQPTGS2AKR1B1TDP1IDO1 | |
| SCHEMBL6864363 | 0.86 | POLQ (0.58) | POLQPTGS2TDP1IDO1SIGMAR1 | |
| SCHEMBL29718842 | 0.85 | PTGS2 (0.49) | POLQPTGS2AKR1B1TDP1SIGMAR1 | |
| SCHEMBL9892644 | 0.85 | PTGS2 (0.52) | POLQPTGS2AKR1B1TDP1ALDH1A1 | |
| SCHEMBL3862724 | 0.85 | POLQ (0.58) | POLQPTGS2TDP1IDO1SIGMAR1 | |
| SCHEMBL18535538 | 0.85 | AKR1B1 (0.52) | POLQPTGS2AKR1B1TDP1EPHX2 | |
| SCHEMBL6971669 | 0.84 | POLQ (0.57) | POLQPTGS2TDP1IDO1SIGMAR1 | |
| SCHEMBL538805 | 0.83 | POLB (0.58) | POLQPTGS2TDP1IDO1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 647 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025110550-A1 | COMPLEX FOR GENE DELIVERY | 전남대학교산학협력단 | 2025-05-30 | — | — | WO | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2023035571-A1 | SYNTHESIS METHOD FOR ESAXERENONE AND INTERMEDIATE THEREOF | 上海鼎雅药物化学科技有限公司 | 2023-03-16 | — | — | WO | claimed |
| CN-115784961-A | Synthesis method of oxacillin and intermediate thereof | 上海鼎雅药物化学科技有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-108883399-B | Fenfluramine composition and preparation method thereof | 周格尼克斯国际有限公司 | 2021-06-22 | — | — | CN | claimed |
| EP-3800177-A1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | Zogenix International Limited (GB) | 2021-04-07 | — | — | EP | claimed |
| CN-107565033-B | Nickel oxide film and preparation method thereof, functional material, manufacturing method of film structure and electroluminescent device | 浙江大学 | 2021-02-26 | — | — | CN | claimed |
| EP-3393655-B1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | ZOGENIX INTERNATIONAL LTD (GB) | 2020-12-09 | — | — | EP | claimed |
| CN-108883399-A | Fenfluramine composition and preparation method thereof | 周格尼克斯国际有限公司 | 2018-11-23 | — | — | CN | claimed |
| EP-3393655-A1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | Zogenix International Limited (GB) | 2018-10-31 | — | — | EP | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| EP-1504002-A1 | OPTICALLY ACTIVE &bgr;-AMINOKETONES, OPTICALLY ACTIVE 1,3-AMINOALCOHOLS AND METHOD FOR THE PRODUCTION THEREOF | Aventis Pharma Deutschland GmbH (DE) | 2005-02-09 | — | — | EP | claimed |
| EP-1458701-A1 | METHOD FOR THE PREPARATION OF ESCITALOPRAM | H. Lundbeck A/S (DK) | 2004-09-22 | — | — | EP | claimed |
| WO-2003093259-A1 | OPTICALLY ACTIVE β-AMINOKETONES, OPTICALLY ACTIVE 1,3-AMINOALCOHOLS AND METHOD FOR THE PRODUCTION THEREOF | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | WO | claimed |
| WO-2003051861-A1 | METHOD FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2003-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | POLQ 2157/4885PTGS2 3949/4885AKR1B1 1963/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | POLQ 590/4885PTGS2 3503/4885AKR1B1 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.